stockrow
Friday 6 November 2026
Export TBIO’s income statement to Excel — free account
Telesis Bio Inc.
TBIO Healthcare Medical Devices
Telesis Bio Inc.’s revenue for fiscal 2023 (year ended December 2023) was $27.5 million, roughly unchanged from fiscal 2022.
0.01
0.00
0.00%
Follow TBIO
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM Sep ’24 | Trend | 10 yrs | 2024e | 2025e | 2026e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | 5 | 7 | 11 | 27 | 28 | 14 | +54.7% | 9 | 10 | — | (40.9%) | |
| Gross margin, % | — | — | — | — | — | (84.99) | 55.12 | 38.93 | 56.84 | 61.62 | 56.11 | +146.6 pt | ||||||
| EBT | — | — | — | — | — | (8) | (18) | (39) | (48) | (48) | (45) | +54.8% | ||||||
| EBT margin, % | — | — | — | — | — | (172.78) | (273.80) | (352.66) | (176.59) | (173.40) | (334.81) | (0.6) pt | ||||||
| Net income | — | — | — | 0 | — | (8) | (18) | (39) | (48) | (48) | (46) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | 0.16 | 23.65 | 10.90 | 16.75 | 16.57 | 7.63 | +216.9% | |||||
| Earnings | — | — | — | — | — | (0.28) | (64.76) | (38.49) | (29.68) | (29.50) | (28.20) | +220.4% | ||||||
| Cash flow | — | — | — | — | — | (0.22) | (55.31) | (36.22) | (23.63) | (20.89) | (12.90) | +212.7% | ||||||
| Capex | — | — | — | — | — | 0.00 | (0.73) | (1.83) | (2.73) | (1.18) | (0.55) | n/m | ||||||
| Free cash flow | — | — | — | — | — | (0.22) | (56.04) | (38.05) | (26.36) | (22.07) | (13.45) | +217.0% | ||||||
| Book value | — | — | — | — | — | (0.26) | (91.55) | 89.61 | 28.43 | 0.14 | (15.35) | n/m | ||||||
| Shares, m | — | — | — | — | — | 29 | 0 | 1 | 2 | 2 | 2 | (51.2%) | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | 13.80 | 13.80 | 29.05 | 1.40 | 0.43 | 0.00 | 11.7 | ||||||
| P/B | — | — | — | — | — | 0.00 | 0.00 | 3.53 | 0.82 | 49.44 | 0.00 | 10.8 | ||||||
| EV/Sales | — | — | — | — | — | 19.27 | 19.27 | 22.82 | 0.52 | (0.08) | 0.12 | 12.4 | ||||||
| EV/FCF | — | — | — | — | — | (6.45) | (6.45) | (6.54) | (0.33) | 0.06 | (0.07) | (3.9) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | (6) | (15) | (37) | (39) | (35) | (23) | +52.6% | |||||
| Capex | — | — | — | — | — | 0 | 0 | (2) | (4) | (2) | (1) | +123.3% | ||||||
| Free cash flow | — | — | — | — | — | (6) | (16) | (39) | (43) | (37) | (24) | +54.7% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | 30 | 12 | 83 | 42 | 22 | 1 | (7.1%) | |||||
| Net debt | — | — | — | — | — | 15 | (10) | (69) | (24) | (14) | 2 | n/m | ||||||
| Shareholders’ equity | — | — | — | — | — | (8) | (25) | 91 | 47 | 0 | (27) | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | (21.42) | (67.04) | (54.44) | (49.05) | (64.60) | (73.87) | (43.2) pt | |||||
| ROIC | — | — | — | — | — | 0.00 | 0.00 | (100.19) | (129.18) | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | — | — | 110.65 | 70.74 | (119.27) | (70.58) | (209.49) | 1,013.88 | (320.1) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | 108 | 42 | 229 | 142 | — | +9.6% | |||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.06 | 0.26 | 0.12 | 0.19 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2023 · latest quarter Sep 2024 · fundamentals updated 26 Oct 2026
Telesis Bio Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| BMRA Biomerica, Inc. | $7.4M | — (loss-making) | 11.4× | −8.33% (below 0%: shrinking) | n/m | −199.25% (below 0%: shrinking) | 8.14% | (97.00%) | Compare |
| INBS Intelligent Bio Solutions Inc. | $5.8M | — (loss-making) | — (loss-making) | +51.10% (above 0%: growing) | n/m | −31.59% (below 0%: shrinking) | 43.23% | (360.19%) | Compare |
| TBIO Telesis Bio Inc. | $5.3M | — (loss-making) | — (loss-making) | −71.85% (below 0%: shrinking) | n/m | −17.96% (below 0%: shrinking) | 64.43% | (349.74%) | |
| VNRX VolitionRX Limited | $5.3M | — (loss-making) | — (loss-making) | −1.97% (below 0%: shrinking) | n/m | +18.58% (above 0%: growing) | 100.00% | (1,042.39%) | Compare |
| BDMD Baird Medical Investment Holdings Limited | $5.0M | — (loss-making) | — | — | n/m | −598.12% (below 0%: shrinking) | — | — | Compare |
| NVNO enVVeno Medical Corporation | $4.8M | — (loss-making) | — (loss-making) | +0.32% (above 0%: growing) | n/m | +27.64% (above 0%: growing) | 0.00% | 0.00% | Compare |
| TNON Tenon Medical, Inc. | $4.4M | — (loss-making) | — (loss-making) | +126.77% (above 0%: growing) | n/m | −21.78% (below 0%: shrinking) | 63.64% | (262.24%) | Compare |
| WOK WORK Medical Technology Group LTD | $4.1M | — | — | — | — | −948.94% (below 0%: shrinking) | — | — | Compare |
| TRIB Trinity Biotech PLC | $3.8M | — (loss-making) | — (loss-making) | +43.28% (above 0%: growing) | n/m | +75.24% (above 0%: growing) | 35.43% | (24.53%) | Compare |
| Median of peers | $4.9M | — | — | +21.80% | — | −26.69% | 39.33% | (179.62%) |